--2025/Q1-- / 1.021M--
--2024/Q4-- / 1.657M--
Nov 14, 20242024/Q33.779M / 886.570K--
Aug 8, 20242024/Q21.408M / 786.000K--
May 9, 20242024/Q11.444M / 1.360M--
US Stock MarketDetailed Quotes
LCTX Lineage Cell Therapeutics
- 0.504
- -0.096-16.02%
Close Nov 22 16:00 ET
- 0.520
- +0.016+3.20%
Post 19:59 ET
115.05MMarket Cap-5039P/E (TTM)
0.620High0.500Low15.61MVolume0.620Open0.600Pre Close8.40MTurnover8.40%Turnover RatioLossP/E (Static)228.31MShares1.61052wk High1.74P/B93.63MFloat Cap0.50052wk Low--Dividend TTM185.81MShs Float78.000Historical High--Div YieldTTM20.02%Amplitude0.100Historical Low0.538Avg Price1Lot Size
Lineage Cell Therapeutics Key Stats
Lineage Cell Therapeutics Q3 2024 Earnings Date
Currency：USDNov 14, 2024
| Estimate (YoY) | Actual (YoY) | Vs Estimate (% Chg) | |
| Revenue | 886.57K | 3.78M | +2.89M |
| Beat Est. | -28.85% | +203.29% | +326.25% |
| EPS | -0.04 | -0.02 | +0.02 |
| Beat Est. | 0.00% | +50.00% | +49.87% |
Analyst Rating
Nov 20, 2024
Lineage Cell Therapeutics Earnings Estimates
Revenue
EPS
EBIT
Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement
Currency: USD
Actual
Estimate
Unlock Free Earnings Estimates
Open Account
Lineage Cell Therapeutics Earnings Reports
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data